🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
8.89
-0.18 (-1.98%)
At close: Nov 20, 2026, 4:00 PM EST
8.96
+0.07 (0.79%)
After-hours: Nov 20, 2026, 7:38 PM EST
← View all transcripts

UBS Global Biopharma Conference 2026

Nov 17, 2026

Summary

December brings CLN-978 multi-dose data across three autoimmune indications, while velinotamig advances toward global Phase II development in 2027. CLN-049's pivotal AML study is enrolling, and zipalertinib's frontline NDA is submitted with a February 2027 second-line PDUFA date.

David Dai
Analyst, UBS

Welcome back, everyone. My name is David Dai. I am one of the biotechnology analysts here at UBS. Welcome to our inaugural UBS Healthcare Conference here in London. With us here today, we have Cullinan Therapeutics, and it is a great pleasure to have Nadim Ahmed, Chief Executive Officer, and also Jeff Jones, Chief Medical Officer, with us today. We are diving into some very interesting stuff that Cullinan is working on. Just for the audience here, Cullinan is a very interesting biotech company here. They have two pipeline programs right now. Actually, I would say three right now, right? With their CD19, they have two programs in autoimmune disease with their CD19 and BCMA T-cell engager. They also have one program for FLT3 T-cell engager targeting AML. We will dive into all these three programs today.

Maybe to start things off, Nadim, Jeff, just give a quick background of the overall story of Cullinan and the key programs we should be focusing on.

Nadim Ahmed
President and CEO, Cullinan Therapeutics

Sure. Great to be with you, David, back in my hometown, London. The first thing I would say is, you set it up nicely, we are very pleased to have what we would describe as a leading portfolio of T-cell engagers, clinical-stage T-cell engagers, across immunology and oncology, and we are heading into a very exciting period for the company over the coming weeks and months with multiple milestones. Starting with immunology, CLN-978 is our CD19 T-cell engager, which we are focusing in on rheumatic diseases, and more specifically, lupus, RA, and Sjögren's disease as our first indications. This is where we believe you need to deplete B cells more widely to exert its effect.

We presented the single target dose data earlier in the summer at EULAR, and in just a few weeks, we are looking forward to presenting our first initial multi-dose data, again, across all of those three indications. Velinotamig is our BCMA T-cell engager. Our partner in China has started the first study in SLE. They presented very exciting data at ACR just this past week. With velinotamig, we are really focused in on those diseases that we believe are driven by plasma cells or long-lived plasma cells that are producing these pathogenic autoantibodies. Jeff and his team are in the process of kicking off our ex-China global development program with an initial basket phase I/II study in autoimmune cytopenias. On the oncology side, we have CLN-049. That is our FLT3 T-cell engager addressing AML.

We had a very positive end of phase I meeting with the FDA. We've started our pivotal study in relapsed/refractory AML. The study's active, we're recruiting patients. We're excited about that study and the data that's upcoming at ASH. Zipalertinib is not a T-cell engager, it's an oral tyrosine kinase inhibitor addressing exon 20 non-small cell lung cancer. We were very pleased just a few weeks ago to present the frontline data at the World Conference on Lung Cancer, where we saw the best PFS results we've seen in the frontline setting of exon 20, which we were very excited about. That's a program we're developing with our partners at Taiho Oncology. We just announced last week, we completed our first-line NDA submission to the FDA under the Real-Time Oncology Review process, or RTOR process.

The other aspect of zipalertinib is, for us, it's also a strategic asset in the sense that it is a source of near-term non-dilutive capital. We're owed regulatory milestones for the frontline and second-line indication approval in the U.S., as well as a 50/50 profit share in the U.S. That allows us to take those funds and put them back in to support our exciting T-cell engager program in immunology and oncology. I hope that provided you and the audience a snapshot of where we are.

David Dai
Analyst, UBS

This is a great background. Yeah, thank you, Nadim, for all that. Let's dive into the CD19 BCMA T-cell engager first, which is, you have one dataset that's coming up, right, in 4Q, where you're going to show some additional data in repeat dose data for RA and SLE, lupus, as well as Sjögren's disease. It helps a level set that the competitive landscape overall, or treatment landscape, I would say, for rheumatology overall, right? Where do you see T-cell engager, you have two right now, CD3, BCMA, and/or CD19 T-cell engagers. Where do you see that fit into the current treatment landscape right now?

Nadim Ahmed
President and CEO, Cullinan Therapeutics

Sure. Jeff can finish that one.

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Yeah, sure. So, maybe first thinking about what is the current treatment landscape, and because we are talking about a lot of different diseases, maybe sort of think about it in a generic sense. So, most patients require immune suppression to control their symptoms, and that is delivered on a continuous basis. So once a patient has an established diagnosis, they go on some form of immune suppression, immune modulation, and they continue that in some form without interruption in many cases. So patients are constantly patients. What the prospect of novel therapies like T-cell engagers and the initial proof of concept data provided by CAR T suggests is that there is an opportunity to induce a deep remission that is sufficiently deep that it achieves a durable response without need for ongoing immune suppression.

That can deliver something really impactful for patients, which is what we, at least I think of as treatment-free time. Can you actually go for a period without having to take a tablet every day, an injection every week, an infusion every other month? And that is really the promise of a T-cell engager. So when we think about the two T-cell engagers in our portfolio, as you mentioned, David, we have both a CD19 and a BCMA. And in many of the common rheumatic diseases, B cells are really at the center of the pathophysiology. And there, we think that CD19 is probably the ideal target for a B cell-driven disease, because it has broad coverage of the B cell compartment, but generally leaves intact long-lived plasma cells that are responsible for memory humoral immune responses, including responses to vaccine.

So you can have a deep B cell-depleting effect that preserves a normal immune response, but potentially impact the disease in a way that delivers a treatment-free response. That is the promise of drugs like CLN-978.

David Dai
Analyst, UBS

Got you. Yeah, really, really helpful. And on the CD19 T-cell engager program, CLN-978, what are some differentiating features of that drug compared to other CD19 or CD20 T-cell engagers that we have seen from BLINCYTO or others?

Nadim Ahmed
President and CEO, Cullinan Therapeutics

Yeah, I think adding to what Jeff said, I think rheumatic diseases certainly seem to be a place, or many of them, where the disease is really driven probably by a pathogenic B cell, memory B cell, some other B cell. There, CD19, the advantage it has over CD20 is that it gives more breadth across the B cell compartment. So CD19 does more than what CD20 can do, and that's why we picked CD19 ahead of CD20. In terms of the specific molecular characteristics, so we engineered CLN-978 to have very high affinity for CD19. One, we believe that's good for taking out the B cells and depleting them deeply. Also, as you go further up the B cell lineage and compartment, you start to see CD19 expression start to dim. So the high affinity allows us actually to go further.

It allows us to get into probably plasmablasts, maybe short-lived plasma cells. So I think, again, it gives us that extended B cell coverage. We also have a molecule that has a very small size relative to many of the other CD19 T-cell engagers that are built on IgG backbones. So it's 150 kilodaltons for those molecules plus versus 65 kilodaltons for us, which we think could be important for penetration into tissue. So I think from a molecular differentiation perspective, that's important. I also think it's important to be first. I'm a commercial person. I would like to be first. Look, we presented the first company-sponsored data this summer for CD19 T-cell engager. We're about to present the multiple dose data in just a few weeks in December. That will then allow us in 2027 to expand into phase II and then registration studies beyond that.

I think we have a real opportunity now to take a differentiated molecule across multiple diseases, which I think is very exciting. I think the other thing that I would point out here is that some of these are very, very large diseases. So, there's room for more than one molecule here. Again, wanting to be first, but there is room for more than one molecule here. Certainly, the folk that are here from the U.S., you see those commercials every day in some of these large areas. So I think we're very pleased with where we are, both from an executional perspective, but also from a molecular differentiation perspective.

David Dai
Analyst, UBS

Great. Speaking of first, you're probably the first one to show some comprehensive data for your CD19 T-cell engager at EULAR most recently in June, where you showed single target dose response in SLE and RA. Maybe just help us understand more around that dataset we saw here, and how should we think about the durability from here?

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Yeah, so I'll take that. The dataset we presented at EULAR, it's been a great travel year for London. At EULAR, we presented data largely from the single ascending dose phase of the study. Because this is a T-cell engager, it wasn't a proper single ascending dose. Patients received a priming dose on day one and then a higher target dose that was ascending on day eight as a way of mitigating cytokine-related adverse events with delivery of the ascending target dose. But effectively, patients were receiving only a single effective target dose. We really saw some remarkable observations. They were in a limited subset of the patients. Almost all patients had meaningful B cell depletion. The majority had improvement in disease scores that, in the case of SLE, would have met criteria for a response conventionally assessed.

But what we saw more profoundly were patients who had a remission of SLE, despite the fact that they had been withdrawn from all of their chronic immune suppressants prior to starting treatment. We saw something similar in patients with rheumatoid arthritis. In the case of the rheumatoid arthritis patients, we were fortunate to have collaborators at European institutions who obtained biopsies of inflamed synovial tissue as well as normal lymph nodes. What we saw as we escalated the dose was a higher likelihood of not only depleting B cells and ectopic follicular structures in inflamed joints, but also depleting B cells in lymph nodes to a degree that at the highest dose for which we had biopsy data, a 30 microgram dose, we saw complete effacement of the orderly lymph node structure.

The B cells had been depleted to a point where they were no longer interacting with follicular dendritic cells and other cells that sort of form those tight immune structures within lymph nodes. This kind of observation had only been seen before with CAR T. This seen in a patient who had a DAS28 remission despite seven prior disease-modifying therapies. So a remarkable outcome in a patient who shouldn't respond to much of anything after 30 years of RA, and tightly correlated with a key biomarker that has been shown to portend durable response. At that point, to your question about durability, we hadn't had much follow-up time for many of these patients. Our next update for this program in December will be the next opportunity to see how those patients were doing.

Nadim already mentioned we'll have multi-dose data at that time, but it'll also be this opportunity to see how these remarkable responders did over time, and I'm excited for the world to see that data.

David Dai
Analyst, UBS

Yeah. On that front, Jeff, can you just help us understand a little more around what additional data should we be expecting from the repeat dose data, how many patients from Because you're going to be showing data from RA

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

That's right.

David Dai
Analyst, UBS

SLE, as well as Sjögren's disease, and we're actually, the first time we'll see Sjögren's disease data here. Help us understand a little more around how many patients we should be expecting from each cohort, and also what becomes meaningful for each?

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Yeah. In our recent quarterly report, we mentioned that we'd have about 20 patients worth of multi-dose data across indications. There'll be more SLE patients in the dataset. We started that trial earlier by about three quarters than RA and almost a year earlier than Sjögren's. So there'll definitely be more SLE patients. There'll be RA patients, and as you stated, the first patients treated for Sjögren's disease. In the case of RA, we mentioned that those patients, that dataset's enriched for biopsy data. The same is true for the Sjögren's patients. So we'll share single ascending dose data from that part of the trial, as well as the initial multi-dose experience.

And some of those patients will have biopsies paired at baseline and two months post-treatment of labial salivary glands, where you expect to see a lymphoid infiltrate in patients with active disease, and we will be able to see the impact of the T-cell engager on that lymphoid infiltrate and how that correlates with clinical improvement.

David Dai
Analyst, UBS

So in terms of clinical improvement then, Jeff, help us understand a little around SLE and RA. Are we looking at a SLEDAI-2K reduction? Or if so, what kind of remission scores are we looking at? What about durability?

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Yeah

David Dai
Analyst, UBS

With lupus? And if RA, we are looking at DAS28, we are looking at remission. So just put that into context around what would become meaningful.

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Yeah. So, I mean, traditionally, a response in lupus, particularly when medications were added onto background immune suppression, was a 4-point improvement in the SLEDAI score. There are other components of what is the SRI-4, but largely grounded in a 4-point improvement. I would say that for a T-cell engager, that is not very aspirational. What we are really looking for is the kind of response we were talking about before, which is a SLEDAI score of zero, a minimal, if not zero dose of prednisone, and no other need for ongoing immune suppression. So we are looking for a percentage of patients to achieve a DORIS response once we get to what we think is a potential phase II dosing regimen. And then we are going to want that remission to be durable if it is to be clinically meaningful.

When we talk with investigators on the SLE side, they tell us if we could achieve that in 30% of patients, that's 30% more than achieved it currently. That would be quite impactful. If it were durable for six months, that would be sufficient for adoption. On RA, it really is much heterogeneity in the patient population. We're currently enrolling difficult-to-treat RA patients, so these are very treatment-experienced patients. Responses of this nature are not typically observed in RA. 20%, 25% could be impactful. Three and four months of duration, some docs have said, could be quite impactful. It really does depend not only on the indication, but where in the natural history of the disease you find the patient.

Nadim Ahmed
President and CEO, Cullinan Therapeutics

I would add to what Jeff said, Dave. As we think about December more specifically, the three things we're focusing on are safety, obviously, initial clinical activity, and then impact on disease-related biomarkers, as Jeff said. Recognizing that some of these will be newer patients, the durability will come later with more follow-up data. I think as you think about what defines success with this dataset, for example, versus June. In June, as Jeff said, we saw early indicators of disease activity, early indicators of immune reset. With the multi-dose data, we want to see that more consistently across more patients. We want to see more patients enter into a DORIS remission, more patients enter into a DAS28 remission. I think if we see that, then that gives a good idea of what durability will ultimately look like.

David Dai
Analyst, UBS

Got it. Great. That's really good. Definitely looking forward to that dataset in 4Q very soon. Now moving on to velinotamig, BCMA T-cell engager that you recently reported data at ACR that shows some pretty compelling data in SLE. These are China patients, early dose, but we did see eight out of nine patients had the great 4-point reduction in SLEDAI-2K, which is clinically meaningful there. This indicates that this drug is active in some ways. The question then is how you're thinking about the indication of choice for BCMA versus CD19, how you think about the indication prioritization between the two.

Nadim Ahmed
President and CEO, Cullinan Therapeutics

I think our view is, firstly, we believe that CD19 and BCMA are the best targets for autoimmune diseases. That was the reason why we went ahead and did the acquisition of the BCMA asset. We're also thinking about a differentiated development plan for both. As Jeff described earlier, CD19, we're really focused on rheumatic diseases where broad B cell depletion is really important. With velinotamig and BCMA, we're really focusing in on those diseases where we believe that it's long-lived plasma cells that are producing those pathogenic autoantibodies that are driving those diseases. Looking outside of rheumatology. For example, I mentioned earlier, Jeff and his team are kicking off our global development program where we're looking at autoimmune cytopenias, which there's very strong biology to support a BCMA approach. Renal diseases is another one, for example.

I think we feel that we have quite a differentiated positioning as well as a differentiated development plan, and ultimately, we want to bring forward a portfolio that addresses the broadest set of autoimmune diseases, and we believe we can do that with CD19 plus BCMA rather than either target alone. If we have the opportunity, as Jeff said, to redefine those standards of care, ultimately each program has very high commercial potential as well.

David Dai
Analyst, UBS

On BCMA, the field is getting quite hot, especially given the numbers of acquisitions, right? BCMA in vivo CAR Ts and other stuff. How do you think your velinotamig differentiates from things like the in vivo CAR Ts of that nature?

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Yeah, I mean, let me take you back to why we picked this. We looked at other BCMAs to potentially in-license, and what was it that was really compelling about this one? Really, we were very struck by the data generated by Genrix Bio in multiple myeloma. It's now the first BCMA T-cell engager approved in China for relapsed multiple myeloma after three prior lines of therapy since August. In that dataset, we saw that patients had a higher than previously reported likelihood of achieving stringent CR with minimal residual disease negative responses, as compared to approved BCMA T-cell engagers here in Europe and the U.S.

We also saw that the drug was markedly active in patients with extramedullary plasma cell disease, so plasmacytomas, which really suggested a potential to address plasma cells outside of the bone marrow, which is an important consideration in treating patients with autoimmune disease, where the pathogenic cells may live outside of the normal marrow component. So that's what really drew us. From a structural standpoint, high affinity binding to BCMA, lower affinity binding to CD3, and pre-clinically demonstrated a broad cytokine window that seemed likely to produce less cytokine release. In fact, in their phase II study, Genrix showed no higher than Grade 2 CRS, and very few cases of Grade 3 CRS, despite CRS being pretty common in multiple myeloma. In the data that we just presented, we saw this borne out in patients with SLE.

We saw that even giving the drug IV, where cytokine-related adverse events are often more common, we saw no higher than Grade 2 CRS. When the step-up scheme was further optimized, no higher than Grade 1 CRS. As Nadim mentioned, we will be starting our own global development. We will be giving the drug subcutaneously, and the favorable kinetics there are expected to further mitigate the risk for CRS. That minimal CRS with marked efficacy, the majority of patients benefiting, all but one achieving a 4-point reduction in SLEDAI. Maybe even more remarkable in terms of patients with very objective indicators of disease activity, patients with lupus nephritis saw dramatic reductions from 2 g to normalization of urine protein, sometimes as quickly as 29 days after starting therapy, and complete renal responses in patients with lupus nephritis in the early stages of a dose escalation trial.

This really gives us confidence in the potential of the drug, not only in lupus nephritis patients, but potentially other nephrology indications down the line, and really in any other antibody-driven autoimmune process, including autoimmune cytopenias, where we are doing our own trial already.

Nadim Ahmed
President and CEO, Cullinan Therapeutics

These results that Jeff described were seen at 5%-10% of the multiple myeloma dose. There is still plenty of room to go.

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Where I think we also differentiate is while it might seem like we are behind, we are not, it is in quite the same way. We are planning with Genrix Bio to initiate phase II in the China study early in 2027, is the expectation. I think that places us right in the middle of the pack with other developers of BCMA, including some who were the subject of those large M&A transactions earlier this year.

David Dai
Analyst, UBS

Very exciting. Very good. Great. Thanks for that. Moving on to the FLT3 T-cell engager, CLN-049. We saw the most recent ASH abstract. I think the investors did not take it nice. I think the important thing here is some CR/CRh response seems to have gone down from last update. Of course, the investor expectations were pretty high to start with, right? I guess the question is, what did the investors get wrong here? Also, what should we be expecting from the actual ASH presentation? What additional things would we be seeing there?

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

I think maybe at the time of ASH last year, we were continuing dose escalation. In the ASH abstract from this year and in our other recent communications, we've stated that we believe that the dose is the one that looked good last year, which is 12 micrograms per kilogram. If there was an expectation that we might see better responses at higher doses, which is not unreasonable, what we will be able to explain as part of our presentation at ASH is why we settled on the 12 microgram dose as the likely phase II dose that best balances a potential for achieving a CR with restoration of normal hematopoiesis, as well as retained safety in a relapse refractory patient population.

In fact, the composite CR rate, and really here we're talking about the regulatory relevant rate, which is CR plus CRh, is largely the same, 31%-26% this year. There was some dilution of the population by patients who were more heavily pretreated as we enrolled in backfill. Success breeds some of these challenges. As investigators see that a drug works, they think about putting their most challenging patients onto a trial where they have an opportunity to respond. But we know as drug developers and clinical trialists that that can also present some challenges for response rates. I think that's largely the explanation.

But I think what I personally hope, and I think the company does, is that when you walk away from our presentation at ASH in December, you understand why we made the choices we did in the now ongoing phase II, and ultimately, why we have strong conviction that the probability of success in phase II is high. That will be the most important takeaway from our presentation.

David Dai
Analyst, UBS

Yeah. One thing to point out is that you already initiated phase II trial, right?

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Correct.

David Dai
Analyst, UBS

For CLN-049. How are these patients different from the phase I-B dose escalation trial? Anything that can give you confidence the CR rates is going to improve over time?

Jeff Jones
Chief Medical Officer, Cullinan Therapeutics

Yeah, it's a good question. As I mentioned, we started treating more heavily pretreated patients in backfill when we added additional patients to dose levels of interest. It's pretty clear from our data that patients who are less heavily pretreated are more likely to respond. The key change as we moved into phase II is to limit enrollment to patients who've had no more than two prior lines of therapy. Still, this is an unselected patient population with respect to biomarkers. We did not identify any need for FLT3 testing to identify a potential responder. We didn't identify a greater or lesser likelihood to respond based on high-risk genetic features.

That included TP53, where we actually saw numerically higher rates of complete response in TP53 patients, which I ultimately think is not attributable to TP53, but merely for the fact that they were less heavily pretreated and went to clinical trial earlier than maybe another patient might.

Nadim Ahmed
President and CEO, Cullinan Therapeutics

I would add also, we've consistently said that the benchmark here for approval is a CR/CRh rate of 20%-30% and duration of four to six months. ASH will have more granular detail on durability as well. In fact, in our study, the phase I study, when patients go to transplant, which some patients did, they actually go off study. So the durability actually is in non-transplant patients. In a way, the deck is stacked against us. In phase II, we'll be able to include those patients per agreement with the FDA. I think we will be able to provide more granular details around durability. 12 micrograms per kilogram is really the dose to focus in on.

David Dai
Analyst, UBS

So great. We're almost out of time, so maybe just one last question. I would love to talk about zipalertinib but we don't have time, unfortunately. Just in terms of the catalyst path over the next 12 months, 6-12 months, maybe you can just help us highlight what are the key things we should be focusing on?

Nadim Ahmed
President and CEO, Cullinan Therapeutics

Sure. Yeah, I'd say for CLN-978, our CD19 T-cell engager, there's the December update. 2027, we expand into phase II. So that's going to be important development advance for the program. With velinotamig, we're just kicking off our autoimmune cytopenia study. Again, a program that we're moving to phase II in 2027, and then thinking about registration studies for both of those programs. CLN-049, our FLT3 T-cell engager in AML, the pivotal study has started. We're dosing patients, so looking for continued progress there. We also have an ongoing phase I/II study we're about to start in the frontline setting in combination with venetoclax and azacitidine, current standard of care. That's going to be important. Then for zipalertinib, we have a PDUFA date for the second line approval already in February of next year. We've just submitted the frontline NDA submission.

Then, of course, we expect milestone payments as well as 50/50 profit share as we start generating revenue. So it's exciting for us to have an approved product line as a company.

David Dai
Analyst, UBS

Fantastic. We are looking forward to all these key catalysts, and it is going to be a great year in the next 12 months. Looking forward to those updates. Thank you so much for taking this time.

Nadim Ahmed
President and CEO, Cullinan Therapeutics

Appreciate it. Thanks, David.

David Dai
Analyst, UBS

Thanks, guys.

Nadim Ahmed
President and CEO, Cullinan Therapeutics

Thanks, everyone.